Abstract
In this issue of Biological Psychiatry, Mann and colleagues (1) report the results of a double-blind placebo-controlled clinical trial of the opioid antagonist nalmefene in the treatment of 598 alcohol-dependent participants drinking at a moderate or greater alcohol risk level according to the World Health Organization criteria for alcohol risk. The study used a somewhat different design in that the medication (20mg nalmefene or placebo) was taken in a targeted or “as-needed fashion,” that is, on days when participants perceived that they were at high risk for drinking.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
